CN110226756A - 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 - Google Patents
预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 Download PDFInfo
- Publication number
- CN110226756A CN110226756A CN201910527202.4A CN201910527202A CN110226756A CN 110226756 A CN110226756 A CN 110226756A CN 201910527202 A CN201910527202 A CN 201910527202A CN 110226756 A CN110226756 A CN 110226756A
- Authority
- CN
- China
- Prior art keywords
- protein
- disease
- flesh
- diabetic patient
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 46
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 38
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 9
- 239000003531 protein hydrolysate Substances 0.000 claims abstract description 7
- 108010009736 Protein Hydrolysates Proteins 0.000 claims abstract description 4
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 4
- 235000018102 proteins Nutrition 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 108010084695 Pea Proteins Proteins 0.000 claims description 15
- 235000019702 pea protein Nutrition 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 13
- 239000004365 Protease Substances 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 235000019419 proteases Nutrition 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 235000019710 soybean protein Nutrition 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 2
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 230000033001 locomotion Effects 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 abstract description 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract description 10
- 229930182817 methionine Natural products 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 9
- 239000004475 Arginine Substances 0.000 abstract description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract description 5
- 229960000310 isoleucine Drugs 0.000 abstract description 5
- 238000011084 recovery Methods 0.000 abstract description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 230000003950 pathogenic mechanism Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 239000004474 valine Substances 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 229940024606 amino acid Drugs 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 8
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000021120 animal protein Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000013118 diabetic mouse model Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 150000005693 branched-chain amino acids Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229960001518 levocarnitine Drugs 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108090000145 Bacillolysin Proteins 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000035092 Neutral proteases Human genes 0.000 description 2
- 108091005507 Neutral proteases Proteins 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- VSFNAZLYGOOSEY-UHFFFAOYSA-N Imidazolylpropionic acid Natural products OC(=O)CCN1C=CN=C1 VSFNAZLYGOOSEY-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- -1 α-HICA Chemical compound 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及配方食品加工技术领域，具体涉及一种预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法。所述的预防和缓解2型糖尿病患者肌少症的蛋白组件包括以下原料：植物源蛋白和/或植物源蛋白水解物和/或植物源肽类、动物源蛋白和/或动物源蛋白水解物和/或动物源肽类、亮氨酸、异亮氨酸、缬氨酸、谷氨酰胺、精氨酸和蛋氨酸。本发明的预防和缓解2型糖尿病患者肌少症的蛋白组件，根据2型糖尿病患者和肌少症的生理特点、病理机制，针对性补充特定的蛋白营养成分，综合协同调控肌肉指标，减缓肌少症的发生，调节身体机能，有利于身体恢复；本发明还提供其制备方法。
Description
技术领域
本发明涉及配方食品加工技术领域，具体涉及一种预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法。
背景技术
肌少症是指老年人骨骼肌质量和骨骼肌力量及功能下降的一种病症，主要强调骨骼肌量下降，或加上骨骼肌力量下降，或加上骨骼肌功能下降。肌少症在中老年人中非常常见，40岁以上的人每年肌肉丢失量为0.5％-1％，而30％的60岁以上的老人、50％的80岁以上的老人会发生不同程度的肌少症。当肌肉减少30％，将影响肌肉的正常功能。骨骼肌量逐渐减少，肌力逐年下降，并逐步发展到难以站起、平衡障碍、极易摔倒骨折等情况，严重影响老年人的生活质量，增加丧失生活自理能力的风险。有研究显示，老年糖尿病患者多处于骨骼肌营养不良状态，且并发肌少症的老年糖尿病患者往往预后不良。由于体内代谢改变、营养摄人不足等原因，老年糖尿病患者已经成为肌少症的高危人群。
肌少症的病因很多，营养的摄入不足和吸收障碍，活动减少，内分泌因素等都可能导致肌少症。目前，还没有较为针对性的药物用于治疗肌少症，临床上一般采用雄激素、肌肉抑制因子阻断剂等药物，通过促进肌肉生成等方式增加肌肉容量。但激素类的药物副作用不明确，对人体健康有潜在的危害，且价格较昂贵，难以普及。除药物治疗外，增加蛋白摄入量，平衡营养吸收是一种行之有效的预防肌少症的方法。
蛋白质可分为植物蛋白和动物蛋白，虽然植物蛋白和动物蛋白从本质上没有太大的区别，但是在氨基酸组成和数量上有一定的不同。植物蛋白取材来源广泛，但其蛋白的种类和相对数量与人体的要求有一定差距，例如，植物蛋白中缺乏免疫球蛋白，谷类中则相对缺乏赖氨酸等；而且植物蛋白的消化、吸收要比动物蛋白差。动物蛋白相对与人类的营养结构比较吻合，其蛋白质的种类和结构更加接近人体的蛋白结构和数量，而且一般都含有人体必需的8种氨基酸(特别是蛋制品和奶制品)，比植物蛋白质营养价值高；但是畜肉的脂肪和胆固醇含量较高，脂肪主要由饱和脂肪酸组成，食用过多易引起肥胖和高血脂症等疾病，因此膳食中的比例不宜过多。
专利CN2012800190507公开了一种包含α-羟基异己酸的营养组合物，还可以包括乳清蛋白质、益生元纤维、L-肉碱、核苷酸和氨基酸。专利CN2012800190594公开了一种包含α-HICA和十二碳五烯酸的营养组合物，还可以包括乳清蛋白质、益生元纤维、瓜氨酸、α-酮戊二酸、L-肉碱、核苷酸和氨基酸。专利CN2012800190556公开了一种包含α-HICA和α-酮戊二酸的营养组合物，还可以包括乳清蛋白质、益生元纤维、瓜氨酸、十二碳五烯酸、L-肉碱、核苷酸和氨基酸。该系列专利公开的营养组合物均适用于肌少症患者，但是成分相对较为复杂，且含有必要成分α-羟基异己酸、α-HICA、十二碳五烯酸、α-酮戊二酸。
专利CN2018115958717公开了一种能预防和缓解肌少症的营养组合物，采用大豆低聚肽、含锌物质、木糖醇、L-山梨糖醇、膳食纤维混合而成，利用矿物元素锌和大豆低聚肽结合加速肌肉蛋白的合成。但是其营养成分相对单一，且仅含有植物蛋白，缺少人体必须的一些氨基酸，不能满足人体的营养需求。
以上技术方案均不是针对2型糖尿病患者肌少症缓解和预防的组合物设计，而且也不是单纯的蛋白组件，成分复杂，含有多种非蛋白成分。
发明内容
针对现有技术的不足，本发明的目的是提供一种预防和缓解2型糖尿病患者肌少症的蛋白组件，根据2型糖尿病患者和肌少症的生理特点、病理机制，针对性补充特定的蛋白营养成分，综合协同调控肌肉指标，减缓肌少症的发生，调节身体机能，有利于身体恢复；本发明还提供其制备方法。
本发明所述的预防和缓解2型糖尿病患者肌少症的蛋白组件，包括以下质量份数的原料：
植物源蛋白为大豆蛋白、豌豆蛋白中的一种或两种；动物源蛋白的来源为乳、蛋、肉、水产品蛋白中的一种或多种。
植物源蛋白水解物或动物源蛋白水解物为植物源蛋白或动物源蛋白与水混合，经蛋白酶水解得到水解液，再经去溶剂、浓缩、干燥后得到的固体。
植物源肽类或动物源肽类为植物源蛋白或动物源蛋白与水混合，经蛋白酶水解得到水解液，再经去溶剂、浓缩、透析、干燥后得到的固体。
蛋白酶为胰蛋白酶、胃蛋白酶、木瓜蛋白酶、风味蛋白酶中的一种或多种。
亮氨酸、异亮氨酸、缬氨酸、谷氨酰胺、精氨酸和蛋氨酸为市售食品级产品。
蛋白组件适用于年龄60岁以上肾脏正常的2型糖尿病患者或2型糖尿病患者肌少症患者，服用量为每天1-1.5g/kg体重。
此食品最适宜于夜晚睡觉前30min内食用，或运动后30-60min内食用。
蛋白选用优质蛋白，乳蛋白、豌豆蛋白等必需氨基酸含量高、生物效价高、无致敏性。采用双蛋白模式，精心设计两者比例，补充调整关键性氨基酸，将植物源蛋白和动物源蛋白的优点充分结合，避免单一蛋白对人体造成营养不足或不良。单一蛋白可能会引起肠胃菌群某种氨基酸生物分解途径基因表达量增加，例如：酪蛋白会显著提高蛋氨酸和亮氨酸的生物分解途径基因表达量，豌豆蛋白会提高组氨酸合成相关基因的表达量，组氨酸含量偏高的蛋白代谢产生咪唑丙酸，破坏胰岛素信号通路，造成胰岛素抵抗，而成为诱发2型糖尿病发生的原因。
由亮氨酸、异亮氨酸、缬氨酸组成的支链氨基酸以释放胰岛素、释放生长激素的方式促进肌肉增长，显著增加蛋白合成，促进相关激素的释放，如生长激素(GH)、IGF-1(胰岛素样生长因子-1)和胰岛素，并有助于维持合理的睾酮/皮质醇比例；支链氨基酸还具有非常好的抗分解作用，有助于预防蛋白分解和肌肉丢失；精氨酸和谷氨酰胺有利于提高肌少症患者的免疫力，进而有利于肌少症患者康复；具有ACE抑制效果的豌豆蛋白肽能够提高肌力和肌量，因此对肌少症具有缓解和改善作用。
蛋氨酸能显著提高胸肌量，降低腹脂率。饮食中缺乏蛋氨酸会降低胴体品质，表现为肌肉沉积降低、腹脂沉积增加。缺乏蛋氨酸会降低肌肉营养价值，提高肌肉中的无机物含量。蛋氨酸可以改善机体的氧化还原状态，这可能是由于蛋氨酸在机体内可转化为胱氨酸，而胱氨酸是GSH合成的原料。
该蛋白组件根据肌少症生理特点、病理机制、营养素营养作用，针对性补充特定的氨基酸，并结合2型糖尿病患者的身体状况，设计组件里蛋白、肽、氨基酸的组成、比例，从而起到调节肌少症患者身体状态，改善营养状况，有利于症状恢复或减缓恶化。
本发明所述的预防和缓解2型糖尿病患者肌少症的蛋白组件的制备方法，步骤如下：
(1)准备原料；
(2)将原料充分混合；
(3)定量包装，包装量为30-50g/包；
(4)辐照杀菌。
步骤(1)中准备原料包括植物源蛋白水解物、植物源肽类、动物源蛋白水解物、动物源肽类的制备，以及将各种原料按照配比称重。
步骤(2)中原料混合采用干混。
步骤(3)中包装采用自动化定量包装。
步骤(4)中辐照杀菌条件为：60Co-γ射线4k-6kGy，剂量率2.5Gy/min。
与现有技术相比，本发明有以下有益效果：
(1)本发明采用双蛋白模式，组分丰富，各组分之间协同效果强，作用机制途径多，对肌肉多指标有改善影响；
(2)本发明的蛋白组件根据肌少症生理特点、病理机制、营养素营养作用，针对性补充特定的氨基酸，并结合2型糖尿病患者的身体状况，设计组件里蛋白、肽、氨基酸的组成、比例，从而起到调节肌少症患者身体状态，改善营养状况，有利于症状恢复或减缓恶化。
(3)本发明针对肌少症患者身体状态，通过蛋白组合搭配、肽的抗氧化性、ACE抑制特性、支链氨基酸的生理活性，综合协同调控肌肉指标，减缓肌少症发生，同时调节身体机能，有利于肌少症患者身体恢复；
(4)本发明成本低，加工方便，无需特殊设备，避免污染，并且不使用增稠剂、乳化剂等添加剂，保证了成品的安全性与食用性。
附图说明
图1为食用实施例1蛋白组件的小鼠骨骼肌HE染色影响图；
图2为食用实施例2蛋白组件的小鼠骨骼肌HE染色影响图；
图3为食用实施例3蛋白组件的小鼠骨骼肌HE染色影响图；
图4为食用对比例1产品的小鼠骨骼肌HE染色影响图；
图5为食用对比例2产品的小鼠骨骼肌HE染色影响图；
图6为空白组小鼠骨骼肌HE染色影响图。
具体实施方式
以下结合实施例对本发明做进一步说明，但本发明的保护范围不仅限于此。
实施例1-3
实施例1-3和对比例1-2的蛋白组件原料组成如表1所示：
表1实施例1-3的蛋白组件原料组成
制备方法如下：
(1)准备原料：
豌豆蛋白购自烟台双塔食品有限公司；乳蛋白购自山东省圣海保健品有限公司；亮氨酸、异亮氨酸、缬氨酸、谷氨酰胺、精氨酸和蛋氨酸购自山东省圣海保健品有限公司。
豌豆蛋白水解物制备方法为：将豌豆蛋白与水混合，水分含量为23-27％，在机筒温度58-60℃，螺杆转速为165-175r/min，模孔孔径为11-13mm的条件下进行双螺杆挤压，将挤出物冷却、干燥、粉碎至60目，然后加水至底物浓度为7％(g/ml)，在加酶量12％(E/S)、温度61℃、pH值6.56条件下酶解，得豌豆蛋白酶解液，经去溶剂、浓缩、干燥，得到豌豆蛋白水解物。
豌豆蛋白低聚肽的制备方法为：将豌豆蛋白与水混合，水分含量为23-27％，在机筒温度58-60℃，螺杆转速为165-175r/min，模孔孔径为11-13mm的条件下进行双螺杆挤压，将挤出物冷却、干燥、粉碎至60目，然后加水至底物浓度7％(g/ml)，在加酶量12％(E/S)、温度61℃、pH 6.56条件下酶解，得豌豆蛋白酶解液，经旋转蒸发浓缩去溶剂、过1kda透析袋、冷冻干燥，得到豌豆蛋白低聚肽。
乳蛋白水解物制备方法为：将乳蛋白与水混合，乳蛋白浓度为0.027g/mL，加酶水解，食品级中性蛋白酶添加量2.1％，复合风味蛋白酶添加量6％，在温度45-47℃，pH值8.1-8.3条件下酶解12h，得到乳蛋白酶解液，经去溶剂、浓缩、干燥，得到豌豆蛋白水解物。
乳蛋白低聚肽制备方法为：将乳蛋白与水混合，乳蛋白浓度为0.027g/mL，加酶水解，食品级中性蛋白酶添加量2.1％，复合风味蛋白酶添加量6％，在温度45-47℃，pH值8.1-8.3条件下酶解12h，得到乳蛋白酶解液，经去溶剂、过1kda透析袋、冷冻干燥，得到乳蛋白低聚肽。
按照表1的配方对原料进行称重，备用。
(2)原料混合：将亮氨酸、异亮氨酸、缬氨酸、谷氨酰胺、精氨酸和蛋氨酸混合均匀后，按质量由小到大，依次与其他物质进行混合均匀，粉碎过60目筛。
(3)定量包装：将混合均匀的原料自动包装成30g/袋。
(4)辐照杀菌：辐照杀菌条件为60Co-γ射线4k-6kGy，剂量率2.5Gy/min。
对比例1
将大豆蛋白粉碎过60目筛，定量包装、杀菌方法同实施例。大豆蛋白购自山东圣海保健品有限公司。
对比例2
将乳清蛋白粉碎过60目筛，定量包装、杀菌方法同实施例。乳清蛋白购自山东圣海保健品有限公司。
将实施例1-3和对比例1-2制备的产品进行糖尿病小鼠实验，方法如下：
(1)糖尿病小鼠模型建立：昆明小鼠，普通饲料适应性喂养1周后，断食16h，不断水，然后给予链脲佐菌素(Streptozotocin)100mg/kg体重，用0.1mol/L柠檬酸缓冲液配制成1％溶液，pH4.4)一次性腹腔注射，正常对照组腹腔注射等体积柠檬酸缓冲液。1周后小鼠断尾取血，用血糖仪检测血糖值，以空腹血糖大于11.1mmol/L断定糖尿病小鼠模型造模成功。
(2)将造模成功的小鼠随机分成6组，设置空白组，实施例1-3和对比例1-2的产品按对应设计给予相应的饮食。使用方法为：将产品用15倍质量的食用水溶解均匀，夜晚睡觉前30min内灌胃0.3mL。
各实施例和对比例的糖尿病小鼠骨骼肌HE染色影响如图1-6所示。
各实施例和对比例的小鼠糖尿病指标如表2所示。
表2各实施例和对比例的小鼠糖尿病指标
由表2和图1结果可知，实施例1-3对糖尿病指标和骨骼肌指标影响效果明显改善，优于对比例1-2。对比糖尿病小鼠模型，实施例中糖尿病小鼠模型骨骼肌和糖尿病指标改善优劣顺序为：实施例3、实施例1、实施例2。
Claims (10)
1.一种预防和缓解2型糖尿病患者肌少症的蛋白组件，其特征在于：包括以下质量份数的原料：
2.根据权利要求1所述的预防和缓解2型糖尿病患者肌少症的蛋白组件，其特征在于：植物源蛋白为大豆蛋白、豌豆蛋白中的一种或两种；动物源蛋白的来源为乳、蛋、肉中的一种或多种。
3.根据权利要求1所述的预防和缓解2型糖尿病患者肌少症的蛋白组件，其特征在于：植物源蛋白水解物或动物源蛋白水解物为植物源蛋白或动物源蛋白与水混合，经蛋白酶水解得到水解液，再经去溶剂、浓缩、干燥后得到的固体。
4.根据权利要求1所述的预防和缓解2型糖尿病患者肌少症的蛋白组件，其特征在于：植物源肽类或动物源肽类为植物源蛋白或动物源蛋白与水混合，经蛋白酶水解得到水解液，再经去溶剂、浓缩、透析、干燥后得到的固体。
5.根据权利要求3或4所述的预防和缓解2型糖尿病患者肌少症的蛋白组件，其特征在于：蛋白酶为胰蛋白酶、胃蛋白酶、木瓜蛋白酶、风味蛋白酶中的一种或多种。
6.根据权利要求1所述的预防和缓解2型糖尿病患者肌少症的蛋白组件，其特征在于：蛋白组件适用于年龄60岁以上肾脏正常的2型糖尿病患者或2型糖尿病患者肌少症患者，服用量为每天1-1.5g/kg体重。
7.根据权利要求1所述的预防和缓解2型糖尿病患者肌少症的蛋白组件，其特征在于：蛋白组件在夜晚睡觉前30min内食用，或运动后30-60min内食用。
8.一种权利要求1所述的预防和缓解2型糖尿病患者肌少症的蛋白组件的制备方法，其特征在于：步骤如下：
(1)准备原料；
(2)将原料充分混合；
(3)定量包装；
(4)辐照杀菌。
9.根据权利要求8所述的预防和缓解2型糖尿病患者肌少症的蛋白组件的制备方法，其特征在于：步骤(3)中定量包装为30-50g/包。
10.根据权利要求8所述的预防和缓解2型糖尿病患者肌少症的蛋白组件的制备方法，其特征在于：步骤(4)中辐照杀菌条件为：60Co-γ射线4k-6kGy，剂量率2.5Gy/min。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910527202.4A CN110226756A (zh) | 2019-06-18 | 2019-06-18 | 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 |
| PCT/CN2019/105499 WO2020252949A1 (zh) | 2019-06-18 | 2019-09-12 | 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910527202.4A CN110226756A (zh) | 2019-06-18 | 2019-06-18 | 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110226756A true CN110226756A (zh) | 2019-09-13 |
Family
ID=67859646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910527202.4A Withdrawn CN110226756A (zh) | 2019-06-18 | 2019-06-18 | 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110226756A (zh) |
| WO (1) | WO2020252949A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113398144A (zh) * | 2021-07-27 | 2021-09-17 | 大连双迪科技股份有限公司 | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012005568A1 (en) * | 2010-07-07 | 2012-01-12 | N.V. Nutricia | Nutritional composition for the stimulation of muscle protein synthesis |
| RU2013151085A (ru) * | 2011-04-18 | 2015-05-27 | Нестек С.А. | ПИТАТЕЛЬНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ α-ГИДРОКСИИЗОКАПРОНОВУЮ КИСЛОТУ(α-HICA), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2014047497A1 (en) * | 2012-09-21 | 2014-03-27 | Abbott Laboratories | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes |
| CN107836708A (zh) * | 2017-10-31 | 2018-03-27 | 北京同仁堂健康药业股份有限公司 | 一种促进肌肉合成的组合物及其制备方法 |
| CN109222103B (zh) * | 2018-11-29 | 2021-04-20 | 汤臣倍健股份有限公司 | 增肌组合物和保健食品 |
-
2019
- 2019-06-18 CN CN201910527202.4A patent/CN110226756A/zh not_active Withdrawn
- 2019-09-12 WO PCT/CN2019/105499 patent/WO2020252949A1/zh active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113398144A (zh) * | 2021-07-27 | 2021-09-17 | 大连双迪科技股份有限公司 | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 |
| CN113398144B (zh) * | 2021-07-27 | 2022-04-01 | 陈玉松 | 核苷酸混合物在制备预防或缓解老年肌少症制剂中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020252949A1 (zh) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278736B (zh) | 一种适合亚洲人群营养支持的均衡肠内全营养制剂 | |
| CN106690290A (zh) | 一种高膳食纤维全营养特殊医学用途配方食品及其制备方法 | |
| CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
| JP2002527457A (ja) | 消化の遅いタン白物質およびその使用 | |
| CN108142927A (zh) | 一种用于满足运动控制体重需求的组合物及其制备方法 | |
| CN108013453A (zh) | 小儿乳糖不耐受专用型临床营养配方及其制备方法 | |
| CN107616490A (zh) | 一种儿童术后专用型临床营养配方及其制备方法 | |
| TWI592153B (zh) | 使用β－羥基－β－甲基丁酸鹽與精胺酸及麩醯胺酸促進糖尿病性潰瘍康復的方法 | |
| CN110074397A (zh) | 一种儿童生长发育专用型临床营养配方及其制备方法 | |
| CN1698448A (zh) | 一种多肽杏仁奶及其制备方法 | |
| CN108308597A (zh) | 一种营养不良专用型临床营养配方及其制备方法 | |
| CN107440102A (zh) | 一种更年期女性专用型临床营养配方及其制备方法 | |
| JP3720496B2 (ja) | 新規ペクチン及びそれを含有する乳化液 | |
| CN107467193B (zh) | 一种以羊奶为基础的粉剂全营养特殊医学用途配方食品及其制备方法 | |
| CN1718117A (zh) | 黑木耳燕麦螺旋藻即冲饮品及其制备方法 | |
| JP2017057147A (ja) | ニンニク等、低塩分濃度の味噌、及びビタミンｂ１を含有する組成物 | |
| CN109170916A (zh) | 一种强身健体食品组合物及其制备方法 | |
| CN110226756A (zh) | 预防和缓解2型糖尿病患者肌少症的蛋白组件及制备方法 | |
| CN1730002A (zh) | 一种补充人体营养元素的维精钙泡腾片制剂及其制备方法 | |
| CN110584120A (zh) | 骨健康组合物 | |
| CN104082656B (zh) | 一种适合肝病病人的营养膳及其制作方法 | |
| CN104430889A (zh) | 一种中老年羊奶粉配方及其制备方法和应用 | |
| KR101782132B1 (ko) | 은행잎 추출물 및 차전자피 분말을 함유한 혈액순환 개선용 건강보조식품 | |
| CN104642795A (zh) | 一种肉兔饲料添加剂 | |
| CN101564084A (zh) | 一种提高动物免疫力的防龋饲料添加剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190913 |